Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. METHODS: In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled adults with biopsy-confirmed IgA nephropathy and proteinuria with a 24-hour urinary protein-to-creatinine ratio of 1 or higher (with protein and creatinine both measured in grams) despite optimized supportive therapy. Patients were randomly assigned, in a 1:1 ratio, to receive oral iptacopan (200 mg) or placebo twice daily for 24 months while continuing to receive supportive therapy. The primary objective of this prespecified interim analysis was to assess the efficacy of iptacopan as compared with that of placebo in reducing proteinuria at month 9; the primary end point was the change from baseline in the 24-hour urinary protein-to-creatinine ratio at month 9. The proportion of patients who had a 24-hour urinary protein-to-creatinine ratio of less than 1 at month 9 without receiving rescue or alternative medication or undergoing kidney-replacement therapy (dialysis or transplantation) was a secondary end point. Safety was also assessed. The effect of iptacopan on kidney function will be assessed at the end of the 2-year double-blind treatment period. RESULTS: The main trial population included 222 patients in the iptacopan group and 221 in the placebo group. The interim efficacy analysis included the first 250 patients who underwent randomization in the main trial population (125 patients in each group) and who remained in the trial until month 9 or discontinued the trial by month 9. Safety was assessed in all the patients in the main trial population. At month 9, the adjusted geometric mean 24-hour urinary protein-to-creatinine ratio was 38.3% (95% confidence interval, 26.0 to 48.6; two-sided P<0.001) lower with iptacopan than with placebo. The reduction in proteinuria was supported by consistent results in secondary end point analyses. There were no unexpected safety findings with iptacopan. The incidence of adverse events that occurred during the treatment period was similar in the two groups; most events were mild to moderate in severity and reversible. No increased risk of infection was observed. CONCLUSIONS: Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, NCT04578834.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationBaigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citationThe incidence of primary glomerulonephritis worldwide: a systematic review of the literature
McGrogan, A., Franssen, C. F. M., & de Vries, C. S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq665 · Cited by 741
Remission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
A graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Current Understanding of the Role of Complement in IgA Nephropathy
Maillard, N., Wyatt, R. J., Julian, B. A., Kiryluk, K., Gharavi, A., Fremeaux-Bacchi, V., & Novak, J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101000 · Cited by 338
Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Reich, H. N., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01554-4 · Cited by 337
Self-citationRovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02302-4 · Cited by 307
Self-citationRoberts, I. S. D. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.92 · Cited by 263
Changing Incidence of Glomerular Disease in Olmsted County, Minnesota: A 30-Year Renal Biopsy Study
Swaminathan, S., Leung, N., Lager, D. J., Melton, L. J., Bergstralh, E. J., Rohlinger, A., & Fervenza, F. C. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00710805 · Cited by 241
Heerspink, H. J. L., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., Inrig, J., Komers, R., Mercer, A., Noronha, I. L., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00569-x · Cited by 224
Self-citationBarratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., et al. (2023) · Kidney International · doi:10.1016/j.kint.2022.09.017 · Cited by 224
Self-citationSmall-molecule factor B inhibitor for the treatment of complement-mediated diseases
Schubart, A., Anderson, K., Mainolfi, N., Sellner, H., Ehara, T., Adams, C. M., Mac Sweeney, A., Liao, S.-M., Crowley, M., Littlewood-Evans, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820892116 · Cited by 223
The role of the immune system in kidney disease
Tecklenborg, J., Clayton, D., Siebert, S., & Coley, S. M. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13119 · Cited by 217
The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy
Rizk, D. V., Maillard, N., Julian, B. A., Knoppova, B., Green, T. J., Novak, J., & Wyatt, R. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00504 · Cited by 175
Self-citationAn update on the pathogenesis and treatment of IgA nephropathy
Boyd, J. K., Cheung, C. K., Molyneux, K., Feehally, J., & Barratt, J. (2012) · Kidney International · doi:10.1038/ki.2011.501 · Cited by 164
Self-citationThe mucosal immune system and IgA nephropathy
Gesualdo, L., Di Leo, V., & Coppo, R. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00871-y · Cited by 159
Judge, P., Staplin, N., Mayne, K., Wanner, C., Green, J., Hauske, S. J., Emberson, J., Preiss, D., Ng, S., Roddick, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00322-4 · Cited by 157
Sim, J. J., Batech, M., Hever, A., Harrison, T. N., Avelar, T., Kanter, M. H., & Jacobsen, S. J. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.03.416 · Cited by 145
Treatment of IgA Nephropathy: A Rapidly Evolving Field
Karoui, K. E., Fervenza, F. C., & Vriese, A. S. D. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000242 · Cited by 132
Zhang, H., Rizk, D. V., Perkovic, V., Maes, B., Kashihara, N., Rovin, B., Trimarchi, H., Sprangers, B., Meier, M., Kollins, D., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.027 · Cited by 131
Self-citationInternational consensus definitions of clinical trial outcomes for kidney failure: 2020
Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F. E., Shahinfar, S., Tuttle, K. R., Donner, J.-A., Jha, V., Nangaku, M., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.07.013 · Cited by 125
Self-citationComplement C5 Mediates Experimental Tubulointerstitial Fibrosis
Boor, P., Konieczny, A., Villa, L., Schult, A. L., Diaeresis]cher, E. B., Rong, S., Kunter, U., van Roeyen, C. R. C., Polakowski, T., Hawlisch, H., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121343 · Cited by 124
Inker, L. A., Heerspink, H. J. L., Tighiouart, H., Chaudhari, J., Miao, S., Diva, U., Mercer, A., Appel, G. B., Donadío, J. V., Floege, J., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.03.007 · Cited by 113
Self-citationRisitano, A. M., Röth, A., Soret, J., Frieri, C., de Fontbrune, F. S., Marano, L., Alashkar, F., Benajiba, L., Marotta, S., Rozenberg, I., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00028-4 · Cited by 110
Is immunoglobulin A nephropathy different in different ethnic populations?
Yeo, S. C., Goh, S. M., & Barratt, J. (2019) · Nephrology · doi:10.1111/nep.13592 · Cited by 99
Self-citationIs IgA nephropathy the same disease in different parts of the world?
Zhang, H., & Barratt, J. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00884-7 · Cited by 91
Self-citationRizk, D. V., Rovin, B. H., Zhang, H., Kashihara, N., Maes, B., Trimarchi, H., Perkovic, V., Meier, M., Kollins, D., Papachristofi, O., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.01.041 · Cited by 78
Self-citationZhang, Y., Yan, X., Zhao, T., Xu, Q., Peng, Q., Hu, R., Quan, S., Zhou, Y., & Xing, G. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12961 · Cited by 64
The Treatment of Primary IgA Nephropathy: Change, Change, Change
Caster, D. J., & Lafayette, R. A. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.08.007 · Cited by 55
Targeting the Endothelin A Receptor in IgA Nephropathy
Kohan, D. E., Barratt, J., Heerspink, H. J. L., Campbell, K. N., Camargo, M., Ogbaa, I., Haile-Meskale, R., Rizk, D. V., & King, A. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.07.023 · Cited by 54
Self-citationAn Update on Current Therapeutic Options in IgA Nephropathy
Lim, R. S., Yeo, S. C., Barratt, J., & Rizk, D. V. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040947 · Cited by 46
Self-citationChallenges in IgA Nephropathy Management: An Era of Complement Inhibition
Tesař, V., Radhakrishnan, J., Charu, V., & Barratt, J. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.06.010 · Cited by 36
Self-citationReich, H. N., & Floege, J. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02710322 · Cited by 16
Cited by
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
Perkovic, V., Trimarchi, H., Tesar, V., Lafayette, R., Wong, M. G., Barratt, J., Suzuki, Y., Liew, A., Zhang, H., Carroll, K., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512133 · Cited by 90
Self-citationIptacopan in IgA Nephropathy — Final 24-Month Data
Barratt, J., Eren, N., Kashihara, N., Maes, B., Rizk, D. V., Rovin, B., Trimarchi, H., Zhang, H., Wang, W., Kocyigit, I., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600743 · Cited by 34
Self-citationHeerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00960-8 · Cited by 12
Self-citationIndividualised treatment effects of corticosteroids in IgA nephropathy
Hölscher, D. L., Schmitz, N. E. J., Niggemeier, L., Pilva, P., Strauch, M., Tesar, V., Barratt, J., Roberts, I. S. D., Coppo, R., Barisoni, L., et al. (2026) · eBioMedicine · doi:10.1016/j.ebiom.2026.106396 · Cited by 2
“With the emergence of novel therapeutic agents 15 and molecular targets, 16 this framework might serve as a blueprint for advancing patient-tailored treatment strategies in IgAN.”
Self-citation
Metadata
- Authors
- Perkovic, V., Barratt, J., Rovin, B., Kashihara, N., Maes, B., Zhang, H., Trimarchi, H., Kollins, D., Papachristofi, O., Jacinto-Sanders, S., Merkel, T., Guerard, N., Renfurm, R., Hach, T., & Rizk, D. V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-02-06
- Volume
- 392
- Issue
- 6
- Pages
- 531-543
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4403759533
- Cited by
- 197
- References
- 34
- FWCI
- 48.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.